Previous studies have reported various mechanisms of hypercoagulation in malignancy, including indirect regulatory mechanisms such as expressing proteins by tumor cells that could alter circulating cells [20–23], and direct regulatory mechanisms such as expressing procoagulant proteins (TF, podoplanin (PDPN)) which directly activate the coagulation cascade/platelets [24–27]. Here, PDPN is linked to neoplasm.